

ASX ANNOUNCEMENT

Investigational New Drug application for TT-034 submitted

Sydney, Australia, 9 December 2013: RNAi-based therapeutics company Benitec Biopharma Limited (ASX Code: BLT) today announced that the Investigational New Drug (IND) application for the company's 'first in man' clinical trial of TT-034 (a ddRNAi-based therapeutic for treating Hepatitis C) was submitted to the US Food and Drug Administration (FDA) on 6 December 2013 in the United States.

Thirty days after filing the IND application, the clinical trial can be initiated, unless the FDA has questions that cannot be answered within that time.

Benitec Biopharma's CEO and Managing Director, Dr Peter French said, "We are delighted to have achieved this major milestone in Benitec's transition to a clinical stage company. The IND is the culmination of years of work by Benitec's subsidiary, Tacere Therapeutics. TT-034 as a 'single shot' treatment for patients with hard to treat active hepatitis C infection will be seen as a disruptive technology in this field if, as we expect, it demonstrates clinical safety and efficacy."

For more information please contact: Dr Peter French | Chief Executive Officer and Managing Director | Phone: +61 (02) 9555 6986 | pfrench@benitec.com | www.benitec.com

About TT-034: TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance, a major problem for most hepatitis C drugs, by simultaneously silencing three separate highly conserved regions on the virus genome. Animal studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.